Background
Methods
Study population
Clinical parameters
Echocardiography
Statistical analysis
Power calculation analysis
Results
Patients’ characteristics
Regensburg | GRASP [17] | TRAMI [19] | MitraSWISS [18] | Pilot Registry [21]a | ACCESS-EU [20] | EVEREST-II [1] | |
---|---|---|---|---|---|---|---|
Year of publication | 2016 | 2016 | 2014 | 2014 | 2013 | 2011 | |
Participants | 102 | 180 | 749 | 74 | 628 | 567 | 184 |
Female [%] | 42.2 | 38.3 | 38.6 | 27 | 36.9 | 36.2 | 38 |
Age [years] | 77.0 ± 5.8 | 71.6 ± 9.8 | 76 (10)b | 72 ± 12 | 74.2 ± 9.7 | 73.7 ± 9.6 | 67.3 ± 12.8 |
MR grade III/IV [%] | 100 | – | 93.8 | 100 | 86.1c | 97.7 | 96 |
DMR [%] | 28.4 | 18.3 | 27.8 | 38 | 22.8 | 20.6 | 74 |
FMR [%] | 71.6 | 81.7 | 71.3 | 62 | 72.0 | 69.3 | 27 |
NYHA III/IV [%] | 75.5 | 81.1 | 89 | – | 85.5 | 84.9 | 52 |
EuroScore II | 5.1 ± 5.9 | 7.6 ± 6.4 | – | – | – | – | – |
LogEuroScore [%] | 26.6 ± 18.0 | – | 20 (19)f | 21 ± 17 | 20.4 ± 16.7 | 23.0 ± 18.3 | – |
Regurgitant orifice area [cm2] | 0.40 ± 0.18 | – | – | – | 0.43 ± 0.16 | – | 0.56 ± 0.38 |
Age [years] | 77.0 ± 5.8 |
Female | 41.4 (12/29) |
Heart rate [bpm] | 74 ± 9 |
Systolic blood pressure [mmHg] | 119 ± 19 |
Diastolic blood pressure [mmHg] | 67 ± 14 |
Body mass index [kg/m2] | 25.8 ± 4.2 |
NT-proBNP [pg/ml] median(P25;75) | 3618 (1619; 5782) |
Serum creatinine [mg/dl] median(P25;75) | 1.1 (1.0; 1.6) |
logEuroScore [%] median(P25;75) | 18.5 (12.7; 32.2) |
NYHA functional class | |
I | 0 (0/29) |
II | 24.1 (7/29) |
III | 62.1 (18/29) |
IV | 13.8 (4/29) |
Comorbidities | |
DCM | 10.3 (3/29) |
Coronary artery disease | 62.1 (18/29) |
Diabetes mellitus II | 34.5 (10/29) |
Medical/Device treatment | |
High-ceiling diuretics | 100 (29/29) |
ACE inhibitors | 48.3 (14/29) |
MRA | 62.1 (18/29) |
Beta-blocker | 89.7 (26/29) |
CRT | 6.9 (2/29) |
MR aetiology | Degenerative | 34.5 (10/29) |
Functional | 65.5 (19/29) | |
MR grading | III | 17.2 (5/29) |
IV | 82.8 (24/29) | |
Vena contracta width [mm] | Degenerative | 7.30 ± 1.34 |
Functional | 7.79 ± 2.04 | |
ERO [cm2] median (P25;P75) | Degenerative | 0.45 (0.33; 0.61) |
Functional | 0.36 (0.27;0.60) | |
Number of implanted clips | 1 | 51.7 (15/29) |
2 | 48.3 (14/29) |
Effect of PMVR on MR, 6 MW and NT-proBNP levels
Before PMVR | After PMVR | p-value | |
---|---|---|---|
MR grade median (P25;P75) | 4 (3.5;4.0) | 1 (0.5;1.5) | < 0.001 |
6 min walk [m] | 257.5 ± 82.5 | 295.7 ± 96.3 | < 0.01 |
VCA (3D) [cm2] median (P25;P75) | 0.89 (0.65;1.33) | 0.17 (0.09;0.37) | < 0.0001 |
NT-proBNP [pg/ml] median(P25;75) | 3618 (1619;5782) | 3247 (2273;4693) | 0.954 |
LV end-diastolic volume [ml/m2] | 85.0 ± 26.5 | 79.4 ± 23.2 | 0.17 |
LV end-systolic volume [ml/m2] | 49.8 ± 22.2 | 44.7 ± 17.4 | 0.11 |
LV ejection fraction [%] | 42.5 ± 12.5 | 43.6 ± 10.1 | 0.51 |